Sign In
Buy ATRA
$9.63
-0.270 (-2.73%)
At Close: Jun 03, 2026
AlloVir Seeks IPO For Anti-Viral Pipeline Development
03:38pm, Thursday, 16'th Jul 2020
AlloVir has filed to raise $100 million in an IPO. The firm is advancing a pipeline of treatments and preventions for various viral diseases, including Covid19.
Assessing If The Bulls Can Gain Control In CenturyLink (NYSE:CTL)
07:56am, Thursday, 09'th Jul 2020
Value and profitability numbers look really attractive in this stock. Cash-flow multiple also looks compelling.
Atara Biotherapeutics Inc (NASDAQ:ATRA) Shares Sold by Victory Capital Management Inc.
04:12am, Sunday, 05'th Jul 2020
Victory Capital Management Inc. lowered its holdings in Atara Biotherapeutics Inc (NASDAQ:ATRA) by 9.3% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange
Atara Biotherapeutics (NASDAQ:ATRA) Rating Increased to Strong-Buy at BidaskClub
02:30am, Friday, 03'rd Jul 2020
Atara Biotherapeutics (NASDAQ:ATRA) was upgraded by BidaskClub from a “buy” rating to a “strong-buy” rating in a research report issued on Friday, BidAskClub reports. Several other research an
Will Atara Biotherapeutics Continue to Surge Higher?
03:28pm, Wednesday, 01'st Jul 2020
As of late, it has definitely been a great time to be an investor of Atara Biotherapeutics
2 Biotech Stocks That Could Soar in 2020
11:12am, Wednesday, 01'st Jul 2020
Despite the market volatility throughout this year, there are still good prospects in this sector, especially in small-cap biotechnology stocks. If you have cash waiting to be put to work, you might
Atreca (BCEL) Received its Third Buy in a Row - Markets
10:27am, Wednesday, 01'st Jul 2020
After H.C. Wainwright and Cowen & Co. gave Atreca (NASDAQ: BCEL) a Buy rating last month, the company received another
Benzinga's Top Upgrades, Downgrades For June 30, 2020
02:19pm, Tuesday, 30'th Jun 2020
Upgrades * For Crocs Inc (NASDAQ: CROX), Loop Capital upgraded the stock from Hold to Buy. In the first quarter, Crocs showed an EPS of $0.22, compared to $0.36 from the year-ago quarter. The stock
Could AAL, OXY, HOG, COTY, CTL – 5 Debt-Laden Stock Portfolio Actually Score Big?
12:00am, Tuesday, 30'th Jun 2020
What’s common between American Airlines, Centurylink, Coty, Occidental Petroleum, and Harley-Davidson? They are all part of our high leverage portfolio where we advise investors to exercise caution.
Short sellers are letting their Wirecard shorts ride - ValueWalk
06:55pm, Thursday, 25'th Jun 2020
Short sellers have been raking it in on their Wirecard shorts, but most haven't cashed their positions out yet. Analysis from one firm shows
Two Sigma Investments LP Sells 159,628 Shares of Atara Biotherapeutics Inc (NASDAQ:ATRA)
07:08am, Thursday, 25'th Jun 2020
Two Sigma Investments LP decreased its holdings in shares of Atara Biotherapeutics Inc (NASDAQ:ATRA) by 66.3% in the first quarter, according to the company in its most recent Form 13F filing with the
Atara Biotherapeutics Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
08:34pm, Wednesday, 24'th Jun 2020
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases i
BNP Paribas Arbitrage SA Buys 21,150 Shares of Atara Biotherapeutics Inc (NASDAQ:ATRA)
07:54am, Wednesday, 24'th Jun 2020
BNP Paribas Arbitrage SA grew its stake in Atara Biotherapeutics Inc (NASDAQ:ATRA) by 330.3% during the first quarter, according to the company in its most recent filing with the Securities and Exchan
Hedge Funds Have Never Been This Bullish On Atara Biotherapeutics Inc (ATRA)
01:48am, Wednesday, 24'th Jun 2020
In this article we will check out the progression of hedge fund sentiment towards Atara Biotherapeutics Inc (NASDAQ:ATRA) and determine whether it is a good investment right now. We at Insider Monkey
Atara Biotherapeutics Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
12:00am, Wednesday, 24'th Jun 2020
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transforma
